Patients treated for Hodgkin's disease with chemotherapy or with the association of chemotherapy and radiotherapy have an increased risk of secondary leukemia. The aim of this study was to evaluate the leukemogenic risk due to these treatment modalities.
Methods
We performed a case-control study on a population of 1410 patients treated for Hodgkin's disease from 1970 to 1990 in our Institute. Among these patients, we identified 25 cases of secondary leukemia and 3 cases of myelodysplasia, all occurring more than one year after the diagnosis of Hodgkin's disease. Three cases occurred among the patients treated with radiotherapy alone. When we analyzed the risk in relation to the type of treatment (radiotherapy, chemotherapy, or both), the comparisons were relative to patients treated with radiotherapy alone.
Results
We found that chemotherapy alone is associated with a fivefold increased risk (odds ratio = 5.4) compared with radiotherapy alone. When both treatments are used, the risk is not further increased (odds ratio = 4.4). Patients receiving more than 6 courses of chemotherapy have an excess risk (relative risk = 2.5) compared with those treated with 6 courses or less. No increased risk was observed after splenectomy.
Conclusions
This study confirms an increased incidence of secondary leukemia occurring in patients treated for Hodgkin's disease. The increased risk seems to be correlated with the number of courses of alkylating agent therapy, whereas it is unaffected by the addition of radiotherapy.
ArseneauJ.C., SponzoR.W., LevinD.L., SchnipperL.E., BounerH., YoungR.C., CanellosG.P., JohnsonR.E., De VitaV.T.: Nonlymphomatous malignant tumors complicating Hodgkin's disease: possible association with intensive therapy.N. Engl. J. Med., 287: 1119–1122, 1972.
2.
BaccaraniM., BosiA., PapaG.: Second malignancy in patients treated for Hodgkin's disease.Cancer, 46: 1735–1740, 1980.
3.
BergP.D., GoldbergJ.D., SilversteinM.N., WeinfeldA., DonovanP.B., EllisJ.T., LandawS.A., LaszloJ., NajeanY., PisciottaA.V., WassermanL.R.: Increased risk of acute leukemia in polycythemia vera associated with chlorambucil therapy.N. Eng. J. Med., 304: 441–447, 1981.
4.
BergsagelD.E., BaileyA.J., LangleyG.R., McDonaldR.N., WhiteD.F., MillerA.B.: The chemotherapy for plasma-cell myeloma and the incidence of acute leukemia.N. Engl. J. Med., 301: 743–748, 1979.
5.
BlayneyD.W., LongoD.L., YoungR.C., GreeneM.H., HubbardS.M., PostalM.G., DuffeyP.L., De VitaV.T.: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.N. Engl. J. Med., 316: 710–714, 1987.
6.
BoiceJ.D.Jr., GreeneM.H., KillenJ.Y., EllenbergS.S., KeehnR.J., McFaddenE., ChenT.T., FraumeniJ.F.Jr.,: Leukemia and preleukemia after adiuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N.Engl. J. Med., 309: 1079–1084, 1983.
7.
BresloweN.E., DayN.E.: Statistical methods in cancer research. Vol. 1: The analysis of case control studies.Lyon, France: International Agency for Research on Cancer (IARC scientific publications no. 32), 1982.
8.
CanellosG.P., De VitaV.Jr., ArseneauJ.C.: Second malignancies complicating Hodgkin's disease.Lancet, 1: 947–949, 1975.
9.
ChakL.Y., SikicB.I., TuckerM.A., HornsR.C.Jr., CoxR.S.: Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung.J. Clin. Oncol., 2: 385–390, 1984.
10.
ColemanC.A., DixonD.O.: Second malignancies complicating Hodgkin's disease: A Southwest Oncology Group 10-year follow-up.Cancer Treat. Rep., 66: 1023–1033, 1982.
11.
ColemanC.N., KaplanH.S., CoxR.S., VargheseA., ButterfieldP., RosenbergS.A.: Leukemias, non-Hodgkin's lymphomas and solid tumors in patients treated for Hodgkin's disease.Cancer Surveys, 1: 733–744, 1982.
12.
ColemanC.N., WilliamsC.J., FlintA., GlatsteinB.J., RosenbergS.A., KaplanH.S.: Hematologic neoplasia in patients treated for Hodgkin's disease.N. Engl. J. Med., 297: 1249–1252, 1977.
13.
CurtisR.E., BoiceJ.D., StovallM., BernsteinL., GreenbergR.S., FlanneryJ.T., SchwartzA.G., WeyerP., MoloneyW.C., HooverR.N.: Risk of leukemia after chemotherapy and radiation treatment for breast cancer.N. Engl. J. Med., 326: 1745–1751, 1992.
14.
DevereuxS., SelassieT.G., Vaughan HudsonG., Vaughan HudsonB., LinchD.C.: Leukemia following treatment for Hodgkin's disease: Tre British National Lymphoma Investigation Experience.Br. Med. J., 301: 1077–1080, 1990.
15.
De VitaV.T., SerpickA.A., CarboneP.P.: Combination chemotherapy in the treatment of advanced Hodgkin's disease.Ann. Intern. Med., 73: 891–895, 1970.
16.
GlickmanA.S., PajakT.F., GottliebA., NissenN., StutzmanL., CooperM.R.: Second malignant neoplasm in patients successfully treated for Hodgkin's disease. A Cancer and Leukemia Group B study.Cancer Treat. Rep., 66: 1035–1044, 1982.
17.
GreeneM.H., BoiceJ.D.Jr., GreerB.E., BlessingJ.A.: Dembo A.J.: Acute non-lymphocytic leukemia after therapy with alkylating agents for ovarian cancer.N. Engl. J. Med., 307: 1416–1421, 1982.
18.
GreeneM.H., HarrisE.L., GershersonD.M., MalkasianG.D.Jr., MeltonL.J. I.I.I., DemboA.J., BennettJ.M., MoloneyW.C., BoiceJ.D.Jr.,: Melphalan may be a more potent leukemogen than cyclophosphamide.Ann. Intern. Med., 105: 360–367, 1986.
19.
GrunwaldH.W., RosnerF.: Acute myeloid leukemia following treatment of Hodgkin's disease: a review.Cancer, 50: 676–683, 1982.
20.
HaasJ.F., KittelmannB., MehnertW.H., StaneczekW., MohnerM., KaldorJ.M., DayN.E.: Risk of leukemia in ovarian tumor and breast cancer patients following treatment by cyclophosphamide.Br. J. Cancer, 55: 213–218, 1987.
LarsenJ., BrinckerH.: The incidence and characteristics of acute myeloid leukemia arising in Hodgkin's disease.Scand. J. Haematol., 18: 197–206, 1977.
25.
Pedersen-BjergaardJ., LarsenS.O.: Incidence of acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N. Engl. J.Med.,307, 965–971, 1982.
26.
Pedersen-BjergaardJ., PhilipP., MortensenB.T., ErsbollJ., JensenG., PanduroJ., ThomsenM.: Acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome secondary to treatment of other malignant disease. Clinical and cytogenetic characteristics and results of invitro culture of bone marrow and HLA typing.Blood, 57: 712–723, 1981.
27.
Pedersen-BjergaardJ., SpechtL., LarsenS.O., ErsbollJ., StruckJ., HansenM.M., HansenH.H., NissenN.I.: Risk of therapy-related leukemia and preleukemia after Hodgkin's disease.Lancet, 2: 83–88, 1987.
28.
SantoroA., BonadonnaG., BonfanteV., ValagussaP.: Alternating drug combinations in the treatment of advanced Hodgkin's disease.N. Engl. J. Med., 306: 770–775, 1982.
29.
SchlesselmanJ.J.: Case-control Studies: Design, Conduct, Analysis.Oxford University Press, New York, 1982.
30.
TuckerM.A., ColemanC.N., CoxR.S., VargheseA., RosenbergS.A.: Risk of second cancer after treatment for Hodgkin's disease.N. Engl. J. Med., 318: 76–81, 1988.
31.
TuckerM.A., MeadowsA.T., BoiceJ.D., StovallM., OberlinO., StoneB.J., BirchJ., VouteP.A., HooverR.N., FraumeniJ.F.Jr.,: Leukemia after therapy with alkylating agents for childhood cancer.J. Natl. Cancer Inst., 78: 459–464, 1987.
32.
ValagussaP., SantoroA., Fossati-BellaniF., BanfiA., BonadonnaG.: Second acute leukemia and other malignancies following treatment for Hodgkin's disease.J. Clin. Oncol., 4: 830–837, 1986.
33.
ValagussaP., SantoroA., KendaR., Fossati-BellaniF., FranchiF., BanfiA., RilkeF., BonadonnaG.: Second malignancies in Hodgkin's disease. A complication of certain forms of treatment.Br. Med. J., 280: 216–219, 1980.
34.
Van LeeuwenF.E., SomersR., HartA.A.M.: Splenectomy in Hodgkin's disease and second leukemias.Lancet, 2: 210–211, 1987.
